2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
96
Pancreatic Neoplasms
85
Carcinoma, Non-Small-Cell Lung
79
Ovarian Neoplasms
52
Fallopian Tube Neoplasms
48
Triple Negative Breast Neoplasms
42
Lung Neoplasms
32
Neoplasm Metastasis
27
Squamous Cell Carcinoma of Head and Neck
23
Neoplasms
19
Breast Neoplasms, Male
18
Endometrial Neoplasms
17
Uterine Cervical Neoplasms
16
Stomach Neoplasms
16
Melanoma
16
Brenner Tumor
16
Carcinoma, Ovarian Epithelial
15
Esophageal Neoplasms
14
Adenocarcinoma of Lung
13
Inflammatory Breast Neoplasms
11
Cholangiocarcinoma
10
Adenocarcinoma, Bronchiolo-Alveolar
9
Urinary Bladder Neoplasms
8
Unspecified Adult Solid Tumor, Protocol Specific
8
Oropharyngeal Neoplasms
8
Carcinoma, Transitional Cell
8
Adenocarcinoma Of Esophagus
8
Mouth Neoplasms
7
Esophageal Squamous Cell Carcinoma
7
Colorectal Neoplasms
7
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Taxes
×
Clear all
NCT07049055
2026-02-27
Carolyn-USA
Engeneic Pty Limited
Phase 1/2
Recruiting
144 enrolled